The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in the treatment of inflammatory diseases. Boehringer Ingelheim. 2002 Branger J, et al
Dr. Noboru Ashida, Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, 54 Kawaramachi, Shogoin Sakyo-ku, Kyoto 606-8507, Japan. Voice +81-75-751-3465; fax: +81-75-751-3574; ash@kuhp.kyoto.u.ac.jp.